These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 24135154)
1. Toxicity and efficacy of three dose-fractionation regimens of intensity-modulated radiation therapy for localized prostate cancer. Manabe Y; Shibamoto Y; Sugie C; Baba F; Ayakawa S; Nagai A; Takemoto S; Hayashi A; Kawai N; Takeuchi M; Ishikura S; Kohri K; Yanagi T J Radiat Res; 2014 May; 55(3):494-501. PubMed ID: 24135154 [TBL] [Abstract][Full Text] [Related]
2. Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer. Dolezel M; Odrazka K; Zouhar M; Vaculikova M; Sefrova J; Jansa J; Paluska P; Kohlova T; Vanasek J; Kovarik J Strahlenther Onkol; 2015 Apr; 191(4):338-46. PubMed ID: 25589224 [TBL] [Abstract][Full Text] [Related]
3. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287 [TBL] [Abstract][Full Text] [Related]
4. Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor-tracking system for prostate cancer: preliminary results of a phase I/II study. Kitamura K; Shirato H; Shinohara N; Harabayashi T; Onimaru R; Fujita K; Shimizu S; Nonomura K; Koyanagi T; Miyasaka K Cancer J; 2003; 9(4):268-76. PubMed ID: 12967137 [TBL] [Abstract][Full Text] [Related]
6. Long-term results of intensity-modulated radiotherapy with three dose-fractionation regimens for localized prostate cancer. Takemoto S; Shibamoto Y; Sugie C; Manabe Y; Yanagi T; Iwata H; Murai T; Ishikura S J Radiat Res; 2019 Mar; 60(2):221-227. PubMed ID: 30566649 [TBL] [Abstract][Full Text] [Related]
7. Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy. Dolezel M; Odrazka K; Vaculikova M; Vanasek J; Sefrova J; Paluska P; Zouhar M; Jansa J; Macingova Z; Jarosova L; Brodak M; Moravek P; Hartmann I Strahlenther Onkol; 2010 Apr; 186(4):197-202. PubMed ID: 20354663 [TBL] [Abstract][Full Text] [Related]
8. Analysis of late toxicity associated with external beam radiation therapy for prostate cancer with uniform setting of classical 4-field 70 Gy in 35 fractions: a survey study by the Osaka Urological Tumor Radiotherapy Study Group. Yoshioka Y; Suzuki O; Nishimura K; Inoue H; Hara T; Yoshida K; Imai A; Tsujimura A; Nonomura N; Ogawa K J Radiat Res; 2013 Jan; 54(1):113-25. PubMed ID: 22988284 [TBL] [Abstract][Full Text] [Related]
9. Moderately hypofractionated radiotherapy for localized prostate cancer: long-term outcome using IMRT and volumetric IGRT. Guckenberger M; Lawrenz I; Flentje M Strahlenther Onkol; 2014 Jan; 190(1):48-53. PubMed ID: 24196279 [TBL] [Abstract][Full Text] [Related]
10. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome. Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210 [TBL] [Abstract][Full Text] [Related]
11. Postoperative Radiation Therapy for Prostate Cancer: Comparison of Conventional Versus Hypofractionated Radiation Regimens. Tandberg DJ; Oyekunle T; Lee WR; Wu Y; Salama JK; Koontz BF Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):396-405. PubMed ID: 29559284 [TBL] [Abstract][Full Text] [Related]
12. Hypofractionated helical tomotherapy using 2.5-2.6 Gy daily fractions for localized prostate cancer. Lopez Guerra JL; Isa N; Matute R; Russo M; Puebla F; Kim MM; Sanchez-Reyes A; Beltran C; Jaen J; Bourgier C; Marsiglia H Clin Transl Oncol; 2013 Apr; 15(4):271-7. PubMed ID: 22855189 [TBL] [Abstract][Full Text] [Related]
13. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity. Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581 [TBL] [Abstract][Full Text] [Related]